Purpose
Use LYA-212 response study 109 to identify relevant studies, evaluate participation details, and follow deterministic inquiry pathways.
LYA-212 response study 109
Trial detail provides deterministic protocol context, enrollment progress, and site coverage for transparent participation planning. This page separates informational trial summaries from any regulated communication and clearly labels synthetic content boundaries. The contact workflow creates a traceable request record and logs correlated audit events for governance testing. Users can review eligibility summaries, inspect site status, and submit a study team inquiry.
Type: CorporateLast reviewed: 2026-02-01Owner: LegalStatus: Approved
Trust Boundary
Trial information is deterministic and transparently separates public study context from workflow-driven operations.
Next Steps
Apply filters, review protocol context, and submit inquiry workflows directly from linked study pages.
Page Focus
This page is a child route in the trials section. Use the dedicated detail content below and related route links for deeper navigation.
LYA-212 response study 109
Internal ID: TRL-0109
NCT-like: NCT90000108
Objective: Assess efficacy, safety, and patient-reported outcomes using a controlled synthetic protocol.
Endpoints: Primary endpoint is change from baseline at week 24 with key secondary safety measures.
Timeline: 2022-11-21 to 2026-11-21
Inclusion snapshot: protocol-defined adults with condition-specific disease activity and baseline laboratory eligibility.
Exclusion snapshot: recent conflicting therapies, unresolved safety findings, and protocol-prohibited concomitant conditions.
Site Locations
- Site 109 Community Clinic | PI: Dr. Nguyen | Open
- Site 269 Community Clinic | PI: Dr. Harper | Open
- Site 429 Medical Center | PI: Dr. Patel | Open
- Site 589 University Hospital | PI: Dr. Harper | Open
- Site 749 Community Clinic | PI: Dr. Ruiz | Open
- Site 909 Community Clinic | PI: Dr. Kim | Open